Consortia
We facilitate large scale collaboration opportunities to overcome cell and gene therapy challenges.
We utilise our extensive network to bring the right people together and build multi-partner, cross-industry collaborations, to accelerate the progression of cell and gene therapies.
Building Consortia
Our unique operating model allows us to build consortia, mobilising key industry stakeholders to drive understanding around industry challenges.
By harnessing leading industry players and collaboratively sharing learnings and data, we generate the combined knowledge needed to overcome common challenges, at reduced cost and investment risk to each organisation involved.
We are always looking for collaborative solutions to industry challenges, and we have open opportunities to join some of our active or upcoming multi-partner projects.
Why join a consortium with us?
- Utilise our industry network and access shared knowledge and insights from leading players tackling the same challenges
- Reduce cost and investment risk by sharing resources and learning collaboratively
- Benefit from our industry expertise and let us take on risk on behalf of your organisation
- Accelerate problem-solving through tailored, collaborative business models
- Adapt and adopt rapidly by tapping into validated solutions, best practices, and pre-competitive frameworks that accelerate implementation and scale-up
Consortia examples
Below are some examples of active and past consortia we have been involved in.
Adeno-associated virus (AAV) formulation consortium
A cross-industry consortium set up by the Cell and Gene Therapy Catapult to improve the understanding and process optimisation of AAV formulation. Expert organisations are working together to increase understanding of AAV formulation, characterisation and stability. The work of the consortium will include optimising AAV formulations for two different types of AAV, including a serotype that is currently being developed for clinical use.
Consortium organisations: Cell and Gene Therapy Catapult, Croda International Plc; Ikarovec; UCL’s department of Biochemical Engineering.
dbDNA for AAV Manufacture
Combining expertise in gene therapy development and manufacturing to develop an innovative recombinant adeno-associated virus (rAAV) production process. The project will enable CGT Catapult to support other rAAV manufacturers around the UK to establish their own doggybone DNA (dbDNA)-based manufacturing processes.
Consortium organisations: Cell and Gene Therapy Catapult, Complement Therapeutics Ltd; Touchlight.
Process Analytical Technologies (PAT) consortium
The PAT consortium brought together 24 organisations to improve understanding of cell bioprocesses. The project delivered real-time PAT datasets from two T cell bioprocess cycles for use by CGT Catapult and its partner organisations within the PAT consortium. This has helped to address the scientific uncertainty surrounding what is happening with these cells, and monitor their biological systems in real-time as they are modified into cell therapy medicine.
Consortium organisations: ABER Instruments; Anthony Nolan; BD, Bio-Techne; Cambridge Consultants; Cell and Gene Therapy Catapult; ChemoMetec; C-CIT Sensors; Cytiva; Eppendorf; GlaxoSmithKline (GSK); HORIBA; IMSPEX Diagnostics Ltd; Kaiser Optical Systems, an Endress+Hauser company; Ocean Insight; Ori Biotech; Oxford Nanoimaging; Quantex; See-Through; TeloNostiX; Terumo Blood and Cell Technologies; Univercells Technologies.
SMARTER consortium
SMARTER is an EU-funded (Horizon Europe) project developing a smart manufacturing platform for personalised cell therapies. It brings together an interdisciplinary and international team of experts that specialise in cell-therapy development and manufacturing, biomarkers and precision medicine, and bioprocess engineering and sensor creation.
Consortium organisations: Biomarkers and Precision Medicine Unit at the Health Research Institute of the Hospital La Fe, Cell and Gene Therapy Catapult, Leibniz University of Hannover.
UK and Swiss consortium
Integrating process analytical technologies into the manufacturing of cell and gene therapies, reducing the cost of manufacturing to make advanced therapies more affordable to healthcare systems.
Consortium organisations: Cell and Gene Therapy Catapult, DataHow AG, Securecell AG.
News feed
Working on a cell or gene therapy innovation challenge?
Contact us today to find out how we can support you.